http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4808533-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f463cdd10c1958ff555feba31c775dbd |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-55 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-55 |
| filingDate | 1985-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1989-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27007ca0b6f9e846781899dcecc29da8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_146eb8b74360694659846aef14010761 |
| publicationDate | 1989-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-4808533-A |
| titleOfInvention | Method of preventing T-cell blastogenesis |
| abstract | A cell mediated immune response system glycoprotein having a molecular weight of about 90,000 and having at least one sialic acid moiety as a biologically active site is disclosed. The glycoprotein is specifically bound by wheat germ agglutinin and also by the hydrophobically binding ligand Blue A (Cibacron Blue F3G-A) but does not bind to lysine. The glycoprotein is a necessary cofactor with Interleukin-1 in the biosynthesis of T-cell growth factor (I1-2). A process for producing a serum-free and mitogen-free I1-2 in vitro by adding the glycoprotein to a serum-free and mitogen-free interleukin-1 preparation is described. The method for producing the serum-free and mitogen-free Interleukin-1 is also described. A chemically defined T-cell growth culture medium containing the new glycoprotein as the only protein substance is used in the above process and also provides a means for studying regulation of T-cell lymphocyte growth. Inhibitors for the formation of T-cell blasts in cell mediated immunological response provide a powerful new tool for preventing host-graft rejection. These inhibitors are alkylating agents for serine esterase enzymes which have been found to be involved in the cell mediated immunological response system which generates natural Killer (NK) cells, the latter being responsible for graft rejection in a host. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5135719-A |
| priorityDate | 1981-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 53.